![]() |
市場調查報告書
商品編碼
2064960
基因編輯作物市場預測至 2034 年:按作物類型、性狀類型、技術、應用、最終用戶和地區進行全球分析。Gene-Edited Crops Market Forecasts to 2034 - Global Analysis By Crop Type (Cereals & Grains, Fruits & Vegetables, Oilseeds, Pulses & Legumes and Other Crop Types), Trait Type, Technology, Application, End User and Geography |
||||||
根據 Stratistics MRC 的數據,預計到 2026 年,全球基因編輯作物市場規模將達到 68 億美元,並在預測期內以 16.8% 的複合年成長率成長,到 2034 年將達到 235 億美元。
基因改造作物是指利用CRISPR-Cas等先進基因組編輯技術,對其遺傳物質進行精確改造,從而在不引入外源DNA的情況下改良其性狀的植物。這些作物的研發目標是在提高產量、增強抗病性、耐旱性和營養價值的同時,減少對化學肥料和農藥的依賴。與傳統育種方法相比,基因編輯技術能夠實現更快、更精準的改良。基因改造作物被視為未來糧食安全和氣候適應農業的關鍵創新。監管部門日益成長的認可度和生物技術的進步正在推動全球範圍內基因改造作物的研究、開發和商業化進程。
糧食安全面臨的壓力日益增大
隨著人口成長,對高產量、抗逆性強的作物需求日益成長。基因編輯技術能夠精準地改造作物,進而提高產量和營養價值。世界各國政府都在支持研發舉措,以加強糧食價值鏈。農業技術公司也正在投資CRISPR及相關工具,以加速作物研發。農民也逐漸認知到基因編輯品種的益處,並且對它們的認知度正在不斷提高。
法規核准的複雜性
各國標準不一阻礙了全球推廣。冗長的核准流程抑制了對新品種的投資。中小企業難以滿足複雜的合規要求。公眾的質疑也是法規核准的一大障礙。各國政府在平衡創新與安全問題方面也持謹慎態度。
CRISPR技術的進步
CRISPR技術能夠實現精準、經濟、快速的作物基因編輯。農民正受益於產量提升、抗蟲害能力增強以及對氣候變遷的適應性增強。製造商正在開發基於CRISPR技術的解決方案,以適應各種作物的需求。世界各國政府都在資助相關項目,加速CRISPR技術在農業領域的應用。生技公司與研究機構之間的合作正在拓展其應用範圍。這些技術進步正在推動基因編輯作物市場的快速成長。
智慧財產糾紛
相互競爭的專利給開發商和農民帶來了不確定性。法律糾紛會延緩新品種作物的商業化。中小企業難以支付專有技術的授權費用。智慧財產權執法方面的區域差異使全球業務擴張更加複雜。供應商在確保跨司法管轄區合規方面面臨挑戰。這些糾紛阻礙了市場的持續成長。
新冠疫情對基因編輯作物市場產生了複雜的影響。一方面,隨著疫情期間糧食安全成為首要任務,需求增加。研究機構加快了抗性作物的研發計畫。線上平台也促進了生物技術知識和工具的傳播。另一方面,供應鏈中斷延緩了田間試驗和核准程序。經濟的不確定性限制了對生物技術基礎設施的投資。整體而言,疫情起到了催化劑的作用,提高了人們對基因編輯作物的認知,並促進了其長期應用。
在預測期內,糧食細分市場預計將佔據最大的市場佔有率。
預計在預測期內,穀物領域將佔據最大的市場佔有率。這是因為這些主糧作物對全球糧食安全至關重要,並將從基因編輯技術的創新中受益最多。小麥、稻米和玉米的商業農場正逐步採用基因編輯技術。生產商正在投資研發更耐寒、產量更高的基因編輯品種。各國政府透過補貼和先導計畫支持創新。宣傳宣傳活動正在強調穀物的營養價值。基因編輯穀物在全球零售市場的滲透率正在不斷提高。
預計在預測期內,生物製藥應用領域將呈現最高的複合年成長率。
在預測期內,生物製藥應用領域預計將呈現最高的成長率,這主要得益於基因編輯作物(可作為治療性蛋白質和疫苗的生物工廠)需求的不斷成長。研究人員正在探索將作物作為一種經濟高效的藥物生產平台。宣傳宣傳活動強調了生物技術農業在醫療保健領域的作用。各國政府正資助相關舉措,以加速生物製藥創新。生物技術公司與製藥公司之間的合作正在擴大其影響力。新創企業正迅速將基因編輯技術應用於醫療領域。
在預測期內,北美預計將佔據最大的市場佔有率,這得益於其先進的生物技術基礎設施、強大的投資能力以及對基因編輯技術的早期應用。美國和加拿大是農業生物技術領域領先創新者的聚集地。政策框架鼓勵永續的、生物技術主導的農業實踐。私人企業正擴大採用高品質的基因編輯作物。生物技術解決方案在零售市場的滲透在全部區域十分廣泛。學術機構正在積極研究CRISPR技術的應用。
在預測期內,亞太地區預計將呈現最高的複合年成長率,這主要得益於各國政府對生物技術農業舉措的補貼支持。中國、印度和日本等國正大力投資基因編輯研究。價格適中的解決方案正受到中小型農戶的青睞。農村數位化計畫正在擴大生物技術技術的普及範圍。電子商務平台正在助力基因編輯種子向偏遠地區分銷。年輕一代對永續生物技術解決方案的興趣日益濃厚。
According to Stratistics MRC, the Global Gene-Edited Crops Market is accounted for $6.8 billion in 2026 and is expected to reach $23.5 billion by 2034 growing at a CAGR of 16.8% during the forecast period. Gene-edited crops are plants whose genetic material has been precisely modified using advanced genome editing technologies such as CRISPR-Cas systems to improve traits without introducing foreign DNA. These crops are developed to enhance yield, disease resistance, drought tolerance, and nutritional content while reducing reliance on chemical inputs. Gene editing offers faster and more targeted improvements compared to traditional breeding methods. These crops are considered a key innovation for future food security and climate-resilient agriculture. Increasing regulatory acceptance and biotechnology advancements are driving research and commercialization of gene-edited crops worldwide.
Increasing food security pressure
Rising populations are creating demand for higher-yield and resilient crops. Gene-editing technologies allow precise modifications to improve productivity and nutritional value. Governments are supporting research initiatives to strengthen food supply chains. Agritech firms are investing in CRISPR and related tools to accelerate crop development. Awareness among farmers is growing as they recognize the benefits of gene-edited varieties.
Regulatory approval complexities
Different countries enforce varying standards, slowing global adoption. Lengthy approval processes discourage investment in new varieties. Smaller firms struggle to navigate complex compliance requirements. Public skepticism adds further challenges to regulatory acceptance. Governments are cautious about balancing innovation with safety concerns.
CRISPR technology advancements
CRISPR enables precise, cost-effective, and rapid crop modifications. Farmers benefit from improved yields, pest resistance, and climate resilience. Manufacturers are developing CRISPR-based solutions tailored to diverse crops. Governments are funding projects to accelerate CRISPR adoption in agriculture. Partnerships between biotech firms and research institutions are expanding reach. This technological progress is fostering rapid growth in the gene-edited crops market.
Intellectual property disputes
Competing patents create uncertainty for developers and farmers. Legal battles can delay commercialization of new crop varieties. Smaller firms struggle to afford licensing fees for proprietary technologies. Regional differences in IP enforcement complicate global expansion. Vendors face challenges in ensuring compliance across jurisdictions. These disputes are constraining consistent market growth.
Covid-19 had a mixed impact on the gene-edited crops market. On one hand, demand rose as food security became a priority during the pandemic. Research institutions accelerated projects to develop resilient crops. Online platforms supported distribution of biotech knowledge and tools. On the other hand, supply chain disruptions delayed field trials and approvals. Economic uncertainty limited investments in biotech infrastructure. Overall, the pandemic acted as a catalyst, boosting awareness and long-term adoption.
The cereals & grains segment is expected to be the largest during the forecast period
The cereals & grains segment is expected to account for the largest market share during the forecast period as these staple crops are critical for global food security and benefit most from gene-editing innovations. Adoption is strong among commercial farms producing wheat, rice, and maize. Manufacturers are investing in durable and high-yield gene-edited varieties. Governments are supporting innovation through subsidies and pilot projects. Awareness campaigns highlight the importance of cereals in nutrition. Retail penetration of gene-edited cereals is expanding across global markets.
The biopharmaceutical applications segment is expected to have the highest CAGR during the forecast period
Over the forecast period, the biopharmaceutical applications segment is predicted to witness the highest growth rate due to rising demand for gene-edited crops that serve as biofactories for therapeutic proteins and vaccines. Researchers are exploring crops as cost-effective platforms for drug production. Awareness campaigns emphasize the role of biotech agriculture in healthcare. Governments are funding initiatives to accelerate biopharmaceutical innovation. Partnerships between biotech firms and pharmaceutical companies are expanding reach. Startups are rapidly adopting gene-editing for medical applications.
During the forecast period, the North America region is expected to hold the largest market share owing to advanced biotech infrastructure, strong investment capacity, and early adoption of gene-editing technologies. The US and Canada host leading innovators in agricultural biotechnology. Policy frameworks encourage sustainable and biotech-driven farming practices. Commercial enterprises are increasingly deploying premium gene-edited crops. Retail penetration of biotech solutions is widespread across the region. Academic institutions are actively researching CRISPR applications.
Over the forecast period, the Asia Pacific region is anticipated to exhibit the highest CAGR driven by supportive government subsidies for biotech farming initiatives. Countries such as China, India, and Japan are investing heavily in gene-editing research. Affordable solutions are gaining traction among mid-sized farms. Rural digitization programs are expanding access to biotech technologies. E-commerce platforms are helping distribute gene-edited seeds to remote areas. Younger demographics are increasingly drawn to sustainable biotech solutions.
Key players in the market
Some of the key players in Gene-Edited Crops Market include Bayer Crop Science, Corteva Agriscience, Syngenta AG, Pairwise Plants, Editas Medicine, Calyxt Inc., Inari Agriculture, CRISPR Therapeutics, Beam Therapeutics, Precigen Inc., Benson Hill Inc., Tropic Biosciences, KeyGene N.V., Yield10 Bioscience and Sangamo Therapeutics.
In March 2026, Corteva Agriscience announced a comprehensive commercial biologicals update ahead of the Cereals 2026 exhibition at Diddly Squat Farm, highlighting the rapid market expansion of its BlueN(TM) and Utrisha(R) N biostimulants. This product rollout utilizes specialized nitrogen-fixing bacteria to colonize the plant's internal microbiome, enabling crops to capture atmospheric nitrogen continuously and boosting overall resource use efficiency by up to 40 percent.
In June 2025, Syngenta AG finalized the comprehensive integration of Novartis' Strains and Natural Products Collection, a massive repository of genetic strains and natural compounds engineered for agricultural microbiome optimization. This asset acquisition significantly accelerates Syngenta's biologicals pipeline, complementing the production capacity of its newly opened 22,000-square-meter biostimulant manufacturing facility in Orangeburg, South Carolina, which is purpose-built to deliver 16,000 tons of bio-based inputs annually.
Note: Tables for North America, Europe, APAC, South America, and Rest of the World (RoW) are also represented in the same manner as above.